Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitorsBANTSCHEFF, Marcus; EBERHARD, Dirk; READER, Valérie et al.Nature biotechnology (Print). 2007, Vol 25, Num 9, pp 1035-1044, issn 1087-0156, 10 p.Article

Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to imatinib treatment in human chronic myelogenous leukemia cellsXIQUAN LIANG; HAJIVANDI, Mahbod; VEACH, Darren et al.Proteomics (Weinheim. Print). 2006, Vol 6, Num 16, pp 4554-4564, issn 1615-9853, 11 p.Article

Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MSKASYAPA, Chitta; GU, Ting-Lei; NATARAJAN, Lalitha et al.Proteomics (Weinheim. Print). 2009, Vol 9, Num 16, pp 3979-3988, issn 1615-9853, 10 p.Article

Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR―ABL kinaseSHUXIN LI; ZHENGLIN YAO; YANJIN ZHAO et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 16, pp 5279-5282, issn 0960-894X, 4 p.Article

The brc-c-abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cellsALITALO, R.FEBS letters. 1987, Vol 222, Num 2, pp 293-298, issn 0014-5793Article

Abl tyrosine kinases in T-cell signalingJING JIN GU; JAE RYUN RYU; PENDERGAST, Ann Marie et al.Immunological reviews. 2009, Vol 228, pp 170-183, issn 0105-2896, 14 p.Article

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemiaLIHUI WANG; KNIGHT, Katy; LUCAS, Claire et al.Haematologica (Roma). 2006, Vol 91, Num 2, pp 235-239, issn 0390-6078, 5 p.Article

Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitorsSHUANG LÜ; QUN LUO; XIANG HAO et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 23, pp 6964-6968, issn 0960-894X, 5 p.Article

The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylateSCHUSTER, Christine; FORSTER, Karin; DIERKS, Henning et al.Blood. 2003, Vol 101, Num 2, pp 655-663, issn 0006-4971, 9 p.Article

Structure―activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: Toward selective Abl inhibitorsANTCZAK, Christophe; VEACH, Darren R; RAMIREZ, Christina N et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 24, pp 6872-6876, issn 0960-894X, 5 p.Article

New effective inhibitors of the Abelson kinaseKRAUS, George A; GUPTA, Vinayak; MOKHTARIAN, Marjan et al.Bioorganic & medicinal chemistry. 2010, Vol 18, Num 17, pp 6316-6321, issn 0968-0896, 6 p.Article

AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of philadelphia-positive acute lymphoblastic leukemia cellsVERSTOVSEK, Srdan; GOLEMOVIC, Mirna; CORTES, Jorge et al.Cancer. 2005, Vol 104, Num 6, pp 1230-1236, issn 0008-543X, 7 p.Article

Hybrid compounds as new Bcr/Abl inhibitorsDEPINGWANG; ZHANG ZHANG; ZHENGCHAO TU et al.Bioorganic & medicinal chemistry letters (Print). 2011, Vol 21, Num 7, pp 1965-1968, issn 0960-894X, 4 p.Article

Dasatinib : a new step in molecular target therapyOLIVIERI, A; MANZIONE, L.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi42-vi46, SUP6Conference Paper

Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivoLIU, Ke-Jun; HE, Jie-Hua; TALELE, Tanaji T et al.International journal of cancer (Print). 2013, Vol 132, Num 1, pp 224-235, issn 0020-7136, 12 p.Article

Hemin Counteracts the Repression of Bcl-2 and Nrf2 Genes and the Cell Killing Induced by Imatinib in Human Bcr-Abl(+) CML CellsBONOVOLIAS, Ioannis D; TSIFTSOGLOU, Asterios S.Oncology research. 2009, Vol 17, Num 11-12, pp 535-547, issn 0965-0407, 13 p.Article